RCS - Physiomics PLC - Publication of Peer Reviewed Article

PhysiomicsAnnouncement

16/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250416:nRSP1262Fa&default-theme=true

RNS Number : 1262F  Physiomics PLC  16 April 2025

16 April 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Publication of Peer Reviewed Article

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the joint online
publication in collaboration with Ankyra Therapeutics entitled 'A
pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12)
anchored-drug conjugate for the treatment of solid tumors' in the Journal of
Molecular Cancer Therapeutics, American Association for Cancer Research
(AACR). 

 

The full article can be accessed via the following link:

https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-24-1051/754639/A-Pharmacokinetic-and-Pharmacodynamic-Model-of-an
(https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-24-1051/754639/A-Pharmacokinetic-and-Pharmacodynamic-Model-of-an)

 

In the publication, a mathematical modelling-based approach to drug
development is described, where Physiomics supported Ankyra Therapeutics in
determining the mechanism of action and dosing/scheduling of their ANK-101
asset. These results provided valuable insights that guided the translation of
the drug into the clinic, and the design of the phase 1 clinical trial.

 

 

Dr Peter Sargent, CEO, commented:

"We are pleased to announce yet another publication, written in partnership
with one of our long-standing clients, Ankyra Therapeutics. This is our third
publication within three months, not only reflecting the impact of our
expertise and services on supporting successful drug development programmes,
but also the variety of clients we work with.

 

"These publications reflect the growing utility and impact of mathematical
modelling on drug development. With the increasing pressure from regulatory
agencies around the world for drug developers to utilise such techniques,
these publications evidence how well Physiomics is positioned to support its
clients in this growing market".

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0) 1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0) 20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.  

 

About Ankyra Therapeutics

 

Ankyra Therapeutics, a Massachusetts US headquartered business, specialises in
the development of novel immunotherapies for the treatment of cancer. The
business is developing anchored-drug conjugates to trigger long lasting
anti-tumour responses without compromising safety. One such candidate in
development by Ankyra Therapeutic is their Cytokine Class IL-12 (ANK-101)
asset which has successfully entered the clinic.

 

About Immunotherapy

 

Immunotherapy has revolutionised cancer treatment by harnessing the body's
immune system to recognise and attack cancer cells more effectively. Unlike
traditional treatments such as chemotherapy and radiation, which target both
healthy and cancerous cells, immunotherapies provide a more precise and
potentially less toxic approach. With breakthroughs in immune checkpoint
inhibitors, CAR-T cell therapy and cancer vaccines, immunotherapy has improved
survival rates and outcomes for patients with various cancers.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAIAMMTMTIBBLA